Major diabetes breakthrough as world-first drug that STOPS the condition gets green light in the UK
Teplizumab can allow diabetes patients to live 'normal lives' without the need for insulin injections.
1
The decision by the Medicines and Healthcare Regulatory Agency (MHRA) has been hailed by experts as a 'breakthrough moment' that represents a 'turning point' in how the condition is treated.
About 400,000 people in the UK have type 1 diabetes, a lifelong condition which causes the immune system to attack insulin-producing cells in the pancreas.
Insulin helps the body use sugar for energy, and without this hormone, blood sugar levels can become dangerously high.
Unlike type 2 diabetes, where the body is unable to make enough insulin or the insulin you do make doesn't work properly, the cause is less clear.
And while type 2 diabetes can be improved through some simple lifestyle changes, type 1 diabetes requires lifelong treatment through insulin injections or pumps.
Teplizumab trains the immune system to stop attacking pancreatic cells.
It's taken by an IV drip for a minimum of 30 minutes over 14 consecutive days.
The drug, which is already approved in the US, has been authorised for use by the MHRA to delay the onset of stage three type 1 diabetes in adults and children aged eight or over by an average of three years.
Ahmed Moussa, general manager of general medicines UK and Ireland at Sanofi, which makes teplizumab, said: 'One hundred years ago the discovery of insulin revolutionised diabetes care. Today's news marks a big step forward.'
The UK is the first country in Europe to be granted a licence.
I'm a doctor and here are the six diabetes myths you need to know
Type 1 diabetes develops gradually in three stages over months or years.
Stage three is usually when people start to experience blood sugar problems and are diagnosed with the condition.
According to the MHRA, teplizumab is used in people with stage two type 1 diabetes, which is an earlier stage of the disease during which patients are at a high risk of progressing to stage three.
Parth Narendran, a professor of diabetes medicine at the University of Birmingham and The Queen Elizabeth Hospital Birmingham, said: 'Teplizumab essentially trains the immune system to stop attacking the beta cells in the pancreas, allowing the pancreas to produce insulin without interference.
'This can allow eligible patients to live normal lives, delaying the need for insulin injections and the full weight of the disease's daily management by up to three years. It allows people to prepare for disease progression rather than facing an abrupt emergency presentation.'
Following the decision by the MHRA, the cost-effectiveness of teplizumab will be assessed by NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to determine if it can be rolled out on the health service.
Karen Addington, chief executive of the charity Breakthrough T1D, said: 'I am personally delighted and welcome the MHRA's approval of teplizumab.
'After years of research, clinical trials and drug development, we have an incredible breakthrough.'
Reacting to the announcement, Dr Elizabeth Robertson, director of research and clinical at Diabetes UK, said: 'Today's landmark licensing of teplizumab in the UK marks a turning point in the treatment of type 1 diabetes.
'For the first time, we have a medicine that targets the root cause of the condition, offering three precious extra years free from the relentless demands of managing type 1 diabetes.'
Dr Robertson added that the 'next steps are critical'.
'To ensure teplizumab reaches everyone who could benefit, we need it to be made available on the NHS, and the rollout of a screening programme to identify those with early-stage type 1 diabetes,' she said.
How do you know if you have type 1 diabetes?
The most common symptoms of type 1 diabetes are:
peeing more than usual
feeling very thirsty
feeling very tired
losing weight quickly without trying to
Other symptoms can include:
The symptoms develop quickly, over a few days or weeks.
If it's not treated, it can lead to a serious condition called diabetic ketoacidosis.
The condition usually starts in children and young adults, but it can happen at any age.
You're more likely to get it if you have other problems with your immune system (autoimmune conditions), or if others in your family have type 1 diabetes or other autoimmune conditions.
The symptoms are similar to type 2 diabetes, but type 2 diabetes usually develops more slowly and is more common in older people.
Source: NHS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
29 minutes ago
- The Independent
‘I'd rather die than go back there': How a vulnerable teenager was failed by a scandal-hit hospital
Traumatised by months of forced feeding and isolation from her family on a secure psychiatric ward, 14-year-old Ruth Szymankiewicz fled her family home through a toilet window and flung herself into a freezing pond in a desperate attempt to get someone to listen. 'I'd rather die than go back to Huntercombe,' the teenager had warned just hours before her father Mark, dragged her from the icy water near their Berkshire home just after Christmas 2021. Two months later, Ruth was dead. The teenager died in hospital two days after having self-harmed when she was left unsupervised at Huntercombe Hospital in Maidenhead, where she should have had constant supervision. Her death sparked a three-year-long police investigation, which found the agency worker responsible for her care was working under a fake name and had completed just a day or a day and a half of online training before his first shift on the understaffed ward Ruth was on. Police were not able to question the worker, known as Ebo Achempong, as he had fled the country. Last week, a jury at her inquest made a rare ruling that her death amounted to an unlawful killing after a litany of failings in her care were uncovered at the 10-day hearing. Ruth, who had an eating disorder, Tourette syndrome and a tic condition, was placed at Huntercombe in October 2021 because her mental health had declined and she required feeding through a tube after refusing to eat. But while there, she was denied therapy to help her manage the often painful and traumatic tube feeding that kept her alive, she was left without regular access to psychologists and was only allowed to see her family twice a week. On a much-anticipated trip home for Christmas in 2021, the teenager was happy to be reunited with her family. But she soon became anxious about her return to Huntercombe and protested over being sent back. The night before she was to return, she self-harmed, and when it was time to leave, she squeezed herself out of a small downstairs toilet window and ran. Her father, Mark, followed her and watched on, horrified, as she entered the "icy bog", pleading with her to come out. When she refused, he pulled her out because she was becoming critically hypothermic, her inquest heard. He carried her back to the house, where the family warmed her up, but when the secure transport finally arrived to take her back to Huntercombe, the situation that unfolded left them 'absolutely broken'. In a statement read at the inquest, Ruth's mother Kate recounted the horrifying ordeal: 'We had to watch our daughter handcuffed and her legs taped together so that they could restrain her to get her into the transport. Our daughter was screaming throughout the whole ordeal. This was a breaking point for Mark and I. 'It absolutely broke us to see our daughter being treated this way and seeing her so distressed, but there was no other option given to us apart from for her to be sectioned and taken to Huntercombe, as nowhere else could help. We felt helpless. I think that Ruth also felt that she could see no way out of this.' Ruth's despair at her time spent on the Thames ward at Huntercombe was laid bare further in a handwritten note found after her death. Addressing it to 'important people', she complained about a lack of therapy for patients like her at the hospital, which she said had an 'unsafe number of staff'. The note read: 'I don't really know who this is really directed to... Huntercombe, it doesn't deserve a capital H. 'It is the s***test mental health institution you could get... the unsafe number of staff, how the place makes you worse, the staff literally sleep on their shifts. I don't want this to happen to any other patients ever. My suggestion is, shut this place down.' Eventually, more than a year after Ruth's death, Huntercombe Maidenhead, or Taplow Manor as it was renamed, was shut after a series of investigations by The Independent and Sky News, which revealed allegations of 'systemic abuse'. Patients sent to Huntercombe Group hospitals revealed how they felt like 'caged animals', with claims they were subjected to painful, bruising restraints, medicated so heavily they felt like 'zombies', and isolated from their families. Ruling that Ruth's death amounted to 'unlawful killing', jurors said there had been systematic failings not only at Huntercombe but by the NHS mental health system that funded her placement at the private equity-owned hospital. Clutching Ruth's stuffed Giraffe as they listened to harrowing evidence of their daughter's time at Huntercombe, her parents described how just a few years earlier, she had been happy. They recounted how their first-born child – a little girl 'with a head of bright red hair' - was a fiery and determined character with a 'huge heart', a 'deep passion for life' and a love of animals and the outdoors. But in December 2020, she suddenly developed physical and vocal tics, and the family faced an 18-month wait to access specialist care. In 2021, she developed an eating disorder and by August, she was admitted to Salisbury Hospital before she was sectioned under the Mental Health Act. Eventually, NHS officials decided she needed to be admitted to a specialist children's mental health unit, and she was taken to Huntercombe. Her parents told the inquest they felt pressured into agreeing to the move, and were soon 'trapped' in a system that was meant to care for Ruth, but instead 'locked her away and harmed her'. During her time at the hospital, the vulnerable teenager was allowed unfettered access to her mobile phone, which she was later found to have used to search for methods of self-harm. Throughout the inquest, multiple staff voiced concerns over short staffing in the unit, with a visibly distressed senior support worker, Michelle Hance, breaking down as she spoke detailed the pressures on workers. Dr Gillian Combe, a senior NHS doctor working for the Thames Valley provider collaborative, which was responsible for Ruth's admission to Huntercombe, admitted that the NHS did not do enough for the 14-year-old. She told the inquest the NHS was aware that the hospital was understaffed daily, and that there were concerns over the care it provided, but there were no other suitable choices available. She appeared to make a plea for more money to build the beds it 'desperately needed'. Standing outside of the Berkshire court room after the inquest concluded, Mark and Kate made a heartfelt plea for Ruth's story to matter: 'Remember Ruth's story. Remember her in the faces of the young people who look to you for help and support.' 'What happened to Ruth is shocking, tragic and harrowing. Whilst there is much more to be said, if change can come from her story, it can make a tangible difference to others.' In response to the ruling, Active Care Group, formerly known as The Huntercombe Group, said: 'We extend our heartfelt condolences to Ruth's family, friends, and all those affected by her passing. We deeply regret the tragic event that occurred, and we are truly sorry for the distress this has caused and recognise the profound impact it has had on everyone who knew her.' The group said it was disappointed that a third-party company it had hired had breached its terms of contract, though it did not state what the breach of contract was. It also said it had made improvements to the quality and safety of its services since.
BBC News
29 minutes ago
- BBC News
West Midlands measles vaccine plea ahead of school term
Parents are being urged by health officials to make sure their children are vaccinated before the return to school as measles cases still circulate in the West of the measles, mumps and rubella (MMR) jabs by age five is as low as 75.8% in parts of the region, according the UK Health Security Agency (UKHSA) - the World Health Organisation recommends a 95% uptake to prevent comes after Birmingham saw an outbreak in 2025 with 26 confirmed cases between January and June, government figures Spence, from the UKHSA, described measles as a "nasty virus" that can spread quickly among unvaccinated children and adults in places like schools and nurseries. "It can lead to serious health problems including ear and chest infections, inflammation of the brain, with some children ending up in hospital and being left with permanent disabilities. Tragically, in rare cases, it can even be fatal," she said."As children under the age of one cannot be vaccinated against measles, it's important siblings are vaccinated to protect little ones and other vulnerable people – including those with weakened immune systems – who are unable to have the MMR vaccine and rely on the rest of us to protect them from measles."She added that if parents are unsure about their child's vaccination record, they can check their Red Book, the NHS app or contact their GP surgery. In 2024, figures from the UKHSA showed 329 of 465 (71%) measles cases across England from October 2023 to February 2024 were in the West Midlands.A GP in the Sparkbrook area of Birmingham said at the time that, in the majority of cases, medics were seeing were in unvaccinated latest measles data from the UKHSA this summer revealed that there have been 674 laboratory-confirmed measles cases reported in England since 1 January, with 145 in 3-31 West Midlands had 34 out of the 674 cases. Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
The Independent
an hour ago
- The Independent
What is MRSA? Symptoms and how to avoid deadly infection after rise in UK cases
There has been a sharp rise in cases of the superbug MRSA being contracted outside hospitals across the UK. Britons have been urged to avoid sharing items such as towels or razors, particularly in gyms and leisure centres where the bacteria has been spreading. Figures show that 175 people were infected with MRSA in the community between January and March this year – a 47 per cent increase on the 119 cases recorded during the same period in 2019. At the same time, those contracting MRSA have been getting younger. Nearly a quarter of community-onset cases in 2023–24 were recorded in people under 45, compared with just one in 10 in 2007 to 2008. The UK Health Security Agency (UKHSA) said it was 'too early' to know if this rise represents a lasting change, but it added that infection rates are being closely tracked. Here, The Independent takes a look at what MRSA is, what the symptoms are, and how to get treated for it: What is MRSA? According to the NHS, MRSA (meticillin-resistant Staphylococcus aureus) is a type of bacteria that usually lives harmlessly on the skin. However, if it gets inside the body, it can cause a serious infection that requires immediate treatment with antibiotics. The UKHSA explains that Staphylococcus aureus is commonly found on human skin and mucosa (the moist, inner lining of some organs and body cavities). In many cases, it causes no problems. But when it enters the body, through broken skin or a medical procedure, it can lead to illnesses ranging from infected eczema and abscesses to pneumonia, joint infections, or bloodstream infections. Most strains of S. aureus can be treated with standard antibiotics, the NHS says, but MRSA is resistant to meticillin and often requires alternative drugs. What are the symptoms of MRSA? The NHS says that many people carry MRSA on their skin without showing symptoms. Problems only arise if the bacteria cause an infection. If MRSA spreads deeper into the body, it can cause more severe symptoms such as: High temperature Chills Dizziness or confusion Breathing difficulties How is MRSA treated? The treatment of MRSA depends on how serious the infection is. Mild MRSA infections may be managed with antibiotic tablets, the NHS says. However, for more severe infections, hospital treatment may be needed. This often involves antibiotics delivered through an injection or a drip. Courses of antibiotics can last from several days to several months, depending on the severity of the infection, according to the NHS. In cases where abscesses or collections of pus form, surgery may be required to drain the infected area. How can MRSA be prevented? The NHS advises that people staying in hospitals or care homes face a higher risk of MRSA, especially if they are undergoing surgery. Visitors are urged to follow strict hygiene instructions, including washing or sanitising their hands. The spread outside of hospital and care settings can be reduced through everyday hygiene measures: Before surgery, patients may be offered an MRSA screening test, the NHS says. This involves taking swabs from the nostrils, mouth or groin. If MRSA is detected, a short course of antibacterial cream, shampoo and body wash is usually prescribed to clear the bacteria before the procedure. The NHS says MRSA can affect anyone, but some people face a higher risk, including those who: The UKHSA warns that while most infections can be treated, resistant strains such as MRSA present more challenges, making prevention and monitoring vital.
